DOCSLIB.ORG

Management of Osteoporosis in Postmenopausal Women: 2010 Position Statement of the North American Menopause Society

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Management of Osteoporosis in Postmenopausal Women: 2010 Position Statement of the North American Menopause Society Menopause: The Journal of The North American Menopause Society Vol. 17, No. 1, pp. 23/24 DOI: 10.1097/gme.0b013e3181cdd4a7 * 2010 by The North American Menopause Society 5 Text printed on acid-free paper NAMS continuing medical education activity Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society This position statement, which begins on page 25, has been COMMERCIAL SUPPORT designated a continuing medical education (CME) activity from The CME activity is supported by an unrestricted educa- The North American Menopause Society (NAMS). tional grant from the Alliance for Better Bone Health, a collaboration between Warner Chilcott plc and its affiliates GOAL and sanofi-aventis (US). To demonstrate an increase in, or affirmation of, current knowledge regarding the management of osteoporosis in ACKNOWLEDGMENTS postmenopausal women. NAMS appreciates the contributions of the following members of the Osteoporosis Editorial Board: Sydney L. Bonnick, MD, FACP, LEARNING OBJECTIVES Medical Director, Clinical Research Center of North Texas, Adjunct After reading this position statement, participants should Professor, Departments of Biology and Kinesiology, University of be able to: North Texas, Denton, TX; Steven T. Harris, MD, FACP, Clinical Professor of Medicine, University of California, San Francisco, San & Describe the effect of menopause and aging on bone Francisco, CA; David L. Kendler, MD, FRCPC, Associate Professor health. of Medicine, University of British Columbia, Vancouver, BC, Canada; Michael R. McClung, MD, Director, Oregon Osteoporosis & Identify risk factors that contribute to fracture risk. Center, Portland, OR; and Stuart L. Silverman, MD, FACP, FACR, & Discuss the assessments of risk factors for fracture and Attending Physician, Cedars-Sinai Medical Center, Clinical Professor how to rule out secondary causes of osteoporosis. of Medicine and Rheumatology, David Geffen School of Medicine, & Identify nonpharmacologic and lifestyle approaches to University of California at Los Angeles, Medical Director, Osteo- prevent bone loss and fractures. porosis Medical Center Clinical Research Center, Beverly Hills, CA. The position statement was reviewed and approved by the 2008- & Review the effects of various therapeutic agents on 2009 NAMS Board of Trustees: JoAnn V. Pinkerton, MD, NCMP preventing osteoporotic fracture; understand their effects (President), Professor of Obstetrics and Gynecology, Vice Chair for on bone density and turnover. Academic Affairs, Director, Midlife Health, University of Virginia & Develop individual treatment strategies to reduce mor- Health Sciences Center, Charlottesville, VA; Cynthia A. Stuenkel, bidity and improve quality of life based on results of MD, NCMP (President-Elect), Clinical Professor of Medicine, University of California, San Diego, La Jolla, CA; Steven R. clinical trials. Goldstein, MD, NCMP (Treasurer), Professor of Obstetrics and & Understand the clinical effects of discontinuing different Gynecology, New York University School of Medicine, New York, antiresorptive and anabolic therapies. NY; Thomas B. Clarkson, DVM (Secretary), Professor of Compa- rative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Elizabeth Contestabile, RN, BScN, NCMP, TARGET AUDIENCE Nurse Educator, Shirley E. Greenberg Women_s Health Centre, The Ottawa Hospital, Riverside Campus, Ottawa, ON, Canada; Robert R. This educational activity has been developed to meet the Freedman, PhD, Professor, Departments of Psychiatry and Obstetrics educational needs of healthcare professionals who provide and Gynecology, Wayne State University School of Medicine, care to postmenopausal women. Detroit, MI; Victor W. Henderson, MD, MS, NCMP, Professor, Departments of Health Research & Policy and of Neurology & ACCREDITATION Neurological Sciences, Stanford University School of Medicine, Stanford, CA; Risa Kagan, MD, FACOG, CCD, NCMP, Clinical The North American Menopause Society (NAMS) is ac- Professor, Department of Obstetrics, Gynecology, and Reproductive credited by the Accreditation Council for Continuing Medical Sciences, University of California, San Francisco, East Bay Physi- Education (ACCME) to provide continuing medical educa- cians Medical Group, Berkeley, CA; JoAnn E. Manson, MD, DrPH, Professor of Medicine and the Elizabeth Fay Brigham Professor of tion for physicians. NAMS designates this educational acti- _ i Women s Health, Harvard Medical School, Chief of Preventive vity for a maximum of 2 AMA PRA Category 1 Credit(s) . Medicine and Co-Director, Connors Center for Women’s Health and Physicians should only claim credit commensurate with the Gender Biology, Brigham and Women_s Hospital, Boston, MA; extent of their participation in the activity. Diane T. Pace, PhD, FNP-BC, CCD, FAANP, NCMP, Assistant Dean for Faculty Practice, Director, Center for Health Evaluation and INSTRUCTIONS Lifestyle Promotion, University of Tennessee Health Science Center, Memphis, TN; Jan L. Shifren, MD, NCMP, Associate Professor of Program participants should complete the CME self- Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical assessment examination provided on page 55. School, Director, Menopause Program, Vincent Obstetrics and Menopause, Vol. 17, No. 1, 2010 23 CONTINUING MEDICAL EDUCATION Gynecology Service, Massachusetts General Hospital, Boston, Novartis, Procter & Gamble, Wyeth; Speaker_s BureauVEli Lilly, MA; Leon Speroff, MD, Professor of Obstetrics and Gynecology, Merck, Procter & Gamble, Roche. Oregon Health and Science University, Portland, OR; Michelle P. For the NAMS Board of Trustees, Dr. Clarkson reports: Warren, MD, Medical Director, Center for Menopause, Hormonal Consultant/Advisory BoardVWyeth; Grants/Research SupportV Disorders, and Women_s Health, Professor of Medicine, Obstetrics Wyeth. Ms. Contestabile reports: No significant financial relation- and Gynecology, Wyeth Professor of Women_s Health, Columbia ships. Dr. Freedman reports: Consultant/Advisory BoardVAlexza Presbyterian Medical Center, Department of Obstetrics and Gynecol- Pharmaceuticals, Depomed, Duramed, Eli Lilly, GlaxoSmithKline, ogy,NewYork,NY;Isaac Schiff, MD (Ex Officio), Joe Vincent Novartis, Organon, Pfizer, Procter & Gamble, Vela Pharmaceuticals, Meigs Professor of Gynecology, Harvard Medical School, Chief, Wyeth. Dr. Goldstein reports: Board of Directors/TrusteesVNYU Vincent Obstetrics and Gynecology Service, Massachusetts General School of Medicine Alumni Corporation; Director, SonoSite; Hospital, Boston, MA; and Wulf H. Utian, MD, PhD, DSc(Med), Consultant/Advisory BoardVBoehringer Ingelheim, Cook Ob/Gyn, NCMP (Ex Officio), Arthur H. Bill Professor Emeritus of Reproduc- Eli Lilly, GlaxoSmithKline, Merck, Novo Nordisk, Pfizer, Philips tive Biology, Case Western Reserve University School of Medicine, Ultrasound, Procter & Gamble, Upsher-Smith; Speaker_sBureauVEli Chairman, Advisory Board, Rapid Medical Research, Consultant, Lilly, Pfizer, Procter & Gamble, Wyeth. Dr. Henderson reports: Obstetrics, Gynecology and Women_s Health Institute, Cleveland Consultant/Advisory BoardVAlexander Foundation for Women_s Clinic, Executive Director, The North American Menopause Society, Health, Council on Menopause Management, Geriatric Neurology Cleveland, OH. Section of the American Academy of Neurology, John Douglas The Society also acknowledges the editorial contributions of French Alzheimer_s Foundation; National Aphasia Association. Margery L.S. Gass, MD, NCMP, NAMS Executive Director Dr. Kagan reports: Consultant/Advisory BoardVAventis, Depomed, Designate, Angela M. Bilancini, NAMS Associate Medical Editor; Eli Lilly, Medtronic, Procter & Gamble, Wyeth; Grants/Research Pamela P. Boggs, MBA, NAMS Director of Education and Devel- SupportVBoehringer Ingelheim, Depomed, Eli Lilly, Novartis, opment; and Kathryn J. Wisch, NAMS Managing Editor. Procter & Gamble; Speaker_s BureauVEli Lilly, GlaxoSmithKline, Novartis, Novogyne. Dr. Manson reports: No significant financial relationships. Dr. Pace reports: Consultant/Advisory BoardVBayer, DISCLOSURE Novo Nordisk, Wyeth; Speaker_s BureauVBayer, King Pharmaceu- NAMS is committed to ensuring balance, independence, and ticals, Novo Nordisk, Pfizer, Wyeth. Dr. Pinkerton reports: Board objectivity in all its educational activities. All those involved in the of Directors/TrusteesVNational Women_s Health Resource Center; development of a continuing medical education (CME) activity are Consultant/Advisory BoardVBoehringer Ingelheim, Duramed, required to disclose financial relationships they or their spouse/partner Merck, Novo Nordisk, Wyeth; Speaker_s BureauVMerck; Research have had during the last 12 months with a commercial interest whose SupportVSolvay, Wyeth. Dr. Shifren reports: Consultant/Advisory products or services are discussed in the CME activity content, or BoardVBoehringer Ingelheim, Eli Lilly, New England Research with any commercial supporters of the activity, over which they have Institutes; Grants/Research Support: Procter & Gamble. Dr. Schiff control. reports: Chair, Medical Advisory BoardVPause, consumer maga- For the Osteoporosis Editorial Board, Dr. Bonnick reports: zine of American College of Obstetricians & Gynecologists. Dr. Advisory BoardVAmgen, Merck, Wyeth; Research SupportV Speroff reports: Consultant/Advisory Board: Warner Chilcott. Dr. Amgen, Merck, Takeda, Wyeth; Speaker_s BureauVAmgen, Novartis, Stuenkel reports: Stock/ShareholderVAbbott Laboratories, Johnson Wyeth. Dr. Harris reports:
Load more

Recommended publications
  • Ipriflavone in the Treatment of Postmenopausal Osteoporosis a Randomized Controlled Trial
    ORIGINAL CONTRIBUTION Ipriflavone in the Treatment of Postmenopausal Osteoporosis A Randomized Controlled Trial Peter Alexandersen, MD Context Data on the efficacy and safety of ipriflavone for prevention of postmeno- Anne Toussaint, MD pausal bone loss are conflicting. Claus Christiansen, MD, PhD Objectives To investigate the effect of oral ipriflavone on prevention of postmeno- pausal bone loss and to assess the safety profile of long-term treatment with iprifla- Jean-Pierre Devogelaer, MD, PhD vone in postmenopausal osteoporotic women. Christian Roux, MD, PhD Design and Setting Prospective, randomized, double-blind, placebo-controlled, 4-year Jacques Fechtenbaum, MD, PhD study conducted in 4 centers in Belgium, Denmark, and Italy from August 1994 to July 1998. Carlo Gennari, MD, PhD Participants Four hundred seventy-four postmenopausal white women, aged 45 Jean Yves Reginster, MD, PhD to 75 years, with bone mineral densities (BMDs) of less than 0.86 g/cm2. for the Ipriflavone Multicenter Interventions Patients were randomly assigned to receive ipriflavone, 200 mg 3 times European Fracture Study per day (n = 234), or placebo (n = 240); all received 500 mg/d of calcium. TUDIES OF IPRIFLAVONE, A SYN- Main Outcome Measures Efficacy measures included spine, hip, and forearm BMD thetic isoflavone derivative, have and biochemical markers of bone resorption (urinary hydroxyproline corrected for cre- atinine and urinary CrossLaps [Osteometer Biotech, Herlev, Denmark] corrected for suggested that it inhibits bone re- creatinine), assessed every 6 months. Laboratory safety measures and adverse events sorption and stimulates osteo- were recorded every 3 months. Sblast activity in vitro in cell cultures1,2 and Results Based on intent-to-treat analysis, after 36 months of treatment, the annual in vivo in experimental models of osteo- 3 percentage change from baseline in BMD of the lumbar spine for ipriflavone vs pla- porosis.
    [Show full text]
  • Botanicals in Postmenopausal Osteoporosis
    nutrients Review Botanicals in Postmenopausal Osteoporosis Wojciech Słupski, Paulina Jawie ´nand Beata Nowak * Department of Pharmacology, Wroclaw Medical University, ul. J. Mikulicza-Radeckiego 2, 50-345 Wrocław, Poland; [email protected] (W.S.); [email protected] (P.J.) * Correspondence: [email protected]; Tel.: +48-607-924-471 Abstract: Osteoporosis is a systemic bone disease characterized by reduced bone mass and the deterioration of bone microarchitecture leading to bone fragility and an increased risk of fractures. Conventional anti-osteoporotic pharmaceutics are effective in the treatment and prophylaxis of osteoporosis, however they are associated with various side effects that push many women into seeking botanicals as an alternative therapy. Traditional folk medicine is a rich source of bioactive compounds waiting for discovery and investigation that might be used in those patients, and therefore botanicals have recently received increasing attention. The aim of this review of literature is to present the comprehensive information about plant-derived compounds that might be used to maintain bone health in perimenopausal and postmenopausal females. Keywords: osteoporosis; menopause; botanicals; herbs 1. Introduction Women’s health and quality of life is modulated and affected strongly by hormone status. An oestrogen level that changes dramatically throughout life determines the Citation: Słupski, W.; Jawie´n,P.; development of women’s age-associated diseases. Age-associated hormonal imbalance Nowak, B. Botanicals in and oestrogen deficiency are involved in the pathogenesis of various diseases, e.g., obesity, Postmenopausal Osteoporosis. autoimmune disease and osteoporosis. Many female patients look for natural biological Nutrients 2021, 13, 1609. https:// products deeply rooted in folk medicine as an alternative to conventional pharmaceutics doi.org/10.3390/nu13051609 used as the prophylaxis of perimenopausal health disturbances.
    [Show full text]
  • Nutriceuticals: Over-The-Counter Products and Osteoporosis
    serum calcium levels are too low, and adequate calcium is not provided by the diet, calcium is taken from bone. Osteoporosis: Clinical Updates Long- term dietary calcium deficiency is a known risk Osteoporosis Clinical Updates is a publication of the National factor for osteo porosis. The recommended daily cal- Osteoporosis Foundation (NOF). Use and reproduction of this publication for educational purposes is permitted and cium intake from diet and supplements combined is encouraged without permission, with proper citation. This 1000 mg/day for people aged 19 to 50 and 1200 mg/ publication may not be used for commercial gain. NOF is a day for people older than 50. For all ages, the tolerable non-profit, 501(c)(3) educational organization. Suggested upper limit is 2500 mg calcium per day. citation: National Osteoporosis Foundation. Osteoporosis Clinical Updates. Issue Title. Washington, DC; Year. Adequate calcium intake is necessary for attaining peak bone mass in early life (until about age 30) and for Please direct all inquiries to: National Osteoporosis slowing the rate of bone loss in later life.3 Although Foundation 1150 17th Street NW Washington, DC 20037, calcium alone (or with vitamin D) has not been shown USA Phone: 1 (202) 223-2226 to prevent estrogen-related bone loss, multiple stud- Fax: 1 (202) 223-1726 www.nof.org ies have found calcium consumption between 650 mg Statement of Educational Purpose and over 1400 mg/day reduces bone loss and increases Osteoporosis Clinical Updates is published to improve lumbar spine BMD.4-6 osteoporosis patient care by providing clinicians with state-of-the-art information and pragmatic strategies on How to take calcium supplements: prevention, diagnosis, and treatment that they may apply in Take calcium supplements with food.
    [Show full text]
  • Regulation of Specific Target Genes and Biological Responses by Estrogen Receptor Subtype Agonists Leitman Et Al
    COPHAR-861; NO. OF PAGES 8 Available online at www.sciencedirect.com Regulation of specific target genes and biological responses by estrogen receptor subtype agonists Dale C Leitman1, Sreenivasan Paruthiyil2, Omar I Vivar1, Elise F Saunier2, Candice B Herber1, Isaac Cohen2, Mary Tagliaferri2 and Terence P Speed3,4 Estrogenic effects are mediated through two estrogen receptor adverse effects. The most troublesome side-effect of (ER) subtypes, ERa and ERb. Estrogens are the most estrogens is the increased risk of breast and endometrial commonly prescribed drugs to treat menopausal conditions, cancer [1,2]. Estrogens also increase blood clotting that but by non-selectively triggering both ERa and ERb pathways can lead to venous thromboembolisms, and possibly in different tissues they can cause serious adverse effects. The strokes and heart disease, particularly in older women different sizes of the binding pockets and sequences of their [1]. activation function domains indicate that ERa and ERb should have different specificities for ligands and biological responses Estrogens in hormone therapy (HT) were formulated that can be exploited for designing safer and more selective long before there was a significant understanding of estrogens. ERa and ERb regulate different genes by binding to the mechanism of action of estrogens. The identification different regulatory elements and recruiting different of ERa and ERb (Figure 1) and the crystal structures of transcription and chromatin remodeling factors that are their ligand binding domain (LBD), the discovery of a expressed in a cell-specific manner. ERa-selective and ERb- variety of coregulatory proteins involved in the genomic selective agonists have been identified that demonstrate that pathway and the demonstration of the nongenomic the two ERs produce distinct biological effects.
    [Show full text]
  • Ipriflavone: an Important Bone-Building Isoflavone
    Ipriflavone: An Important Bone-Building Isoflavone Kathleen A. Head, N.D. Abstract Ipriflavone, an isoflavone synthesized from the soy isoflavone daidzein, holds great promise in the prevention and treatment of osteoporosis and other metabolic bone diseases. It has been widely studied in humans and found effective for inhibiting bone resorption and enhancing bone formation, the net result being an increase in bone density and a decrease in fracture rates in osteoporotic women. While ipriflavone appears to enhance estrogen’s effect, it does not possess intrinsic estrogenic activity, making it an attractive adjunct or alternative to conventional hormone replacement therapy. Preliminary studies have also found ipriflavone effective in preventing bone loss associated with chronic steroid use, immobility, ovariectomy, renal osteodystro- phy, and gonadotrophin hormone-releasing hormone agonists. In addition, it holds prom- ise for the treatment of other metabolic diseases affecting the bones, including Paget’s disease of the bone, hyperparathyroidism, and tinnitus caused by otosclerosis. (Altern Med Rev 1999;4(1):10-22) Introduction Ipriflavone (chemical structure: 7-isopropoxyisoflavone), derived from the soy isoflavone, daidzein, holds great promise for osteoporosis prevention and treatment (see Figure 1). Ipriflavone (IP) was discovered in the 1930s but has only recently begun to be embraced by the medical community in this country. Over 150 studies on safety and effective- ness, both animal and human, have been conducted in Italy, Hungary, and Japan. As of 1997, 2,769 patients had been treated a total of 3,132 patient years.1 Pharmacokinetics IP is metabolized mainly in the liver and excreted in the urine. Food appears to enhance its absorption.
    [Show full text]
  • We Need Drugs That…
    7/5/2016 Disclosures New Osteoporosis Treatments Mary L. Bouxsein, PhD Advisory Board: Merck, Eli Lilly, Radius Department of Orthopedic Surgery Harvard Medical School, Boston, MA Research funding: Merck, Amgen Consulting fees: Acceleron Pharma, Agnovos What we have today We need drugs that… • Treatments that reduce the risk of vertebral • Maintain or promote bone formation fractures by 50 to 80% • Strengthen cortical bone —> reduce Non‐VFx • Treatments that reduce the risk of non‐vertebral fractures by 20‐25% – Non‐vertebral fracture remain major source of disability • Are convenient for patient • Are cost‐effective % of days of disability due to different • Are safe types of fractures Results from FIT II Cummings et al, JAMA 2006 1 7/5/2016 New treatments, new mechanisms of action Cathepsin K and Bone Resorption • CatK is a lysosomal protease highly expressed in osteoclasts, where it is • Cathepsin K inhibitors released during bone resorption Odanacatib (ODN) • CatK is the major protease responsible for degradation of type I collagen • Anti‐sclerostin antibody Romozosumab • Novel PTH Analogs Abaloparitide (BA‐058) Rodan SB et al. IBMS BoneKey. 2008;5:16–24. Global deletion of Cathepsin K in mice decreases bone resorption but increases bone formation Distal femur Serum CTx WT How can cathepsin K inhibition lead to increased bone formation? WT KO Revisiting the ‘coupled’ process of BFR/BS KO bone remodeling WT KO Pennypacker B. et al., Bone, 2009 2 7/5/2016 Coupling of bone formation & resorption Genetic deletion of CatK in osteoclasts Bone mass Bone resorption OPG “Clastokines” Bone formation RANKL Osteoclast # CON OC CatK KO ) * 2 # Oc MDGFs BFR * (IGF1, TGFß) BFR/TV (%/year) Image courtesy of R.
    [Show full text]
  • UC Berkeley UC Berkeley Electronic Theses and Dissertations
    UC Berkeley UC Berkeley Electronic Theses and Dissertations Title Statistical Methods for Dose-Response Assays Permalink https://escholarship.org/uc/item/9295t422 Author Tong, Frances Poyen Publication Date 2010 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California Statistical Methods for Dose-Response Assays by Frances Poyen Tong A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Statistics in the GRADUATE DIVISION of the UNIVERSITY OF CALIFORNIA, BERKELEY Committee in charge: Professor Terence P. Speed, Chair Professor Haiyan Huang Professor John Ngai Professor Deborah Nolan Spring 2010 Statistical Methods for Dose-Response Assays Copyright 2010 by Frances Poyen Tong 1 Abstract Statistical Methods for Dose-Response Assays by Frances Poyen Tong Doctor of Philosophy in Statistics University of California, Berkeley Professor Terence P. Speed, Chair Dose-response assays are a common and increasingly high throughput method of as- sessing the toxicity of potential drug targets on test populations of cells. Such assays typically involve serial dilutions of the compounds in question applied to cell samples to determine the level of cell activity across a broad range of concentrations. Another factor in such experiments may be the change in activity under different enzyme com- binations and the use of controls to adjust for interassay variations. Typically, the decreasing number in the population of cells due to increasing concentrations of the drug can be modeled with a logistic curve. Since the appropriate range of concen- trations of the drug to test in order to see these reactions cannot be predetermined fully, frequently the data available for a given experimental unit may not be enough to fit such curves on their own successfully.
    [Show full text]
  • PRODUCT MONOGRAPH Pr Zoledronic Acid
    PRODUCT MONOGRAPH Pr Zoledronic Acid - A (zoledronic acid injection) 5 mg/100 mL solution for intravenous infusion Bone Metabolism Regulator Sandoz Canada Inc. Date of Revision: 145 Jules-Léger June 01, 2016 Boucherville, QC, Canada J4B 7K8 Control No. : TBD Zoledronic Acid – A Page 1 of 62 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ............................................................ 3 SUMMARY PRODUCT INFORMATION ........................................................................... 3 INDICATIONS AND CLINICAL USE ................................................................................. 3 CONTRAINDICATIONS ....................................................................................................... 4 WARNINGS AND PRECAUTIONS ..................................................................................... 4 ADVERSE REACTIONS ..................................................................................................... 10 DOSAGE AND ADMINISTRATION ................................................................................. 25 OVERDOSAGE ..................................................................................................................... 27 ACTION AND CLINICAL PHARMACOLOGY............................................................... 27 STORAGE AND STABILITY ............................................................................................. 30 SPECIAL HANDLING INSTRUCTIONS .......................................................................... 30
    [Show full text]
  • Current and Potential Future Drug Treatments for Osteoporosis
    700 Annals ofthe Rheumatic Diseases 1996;55:700-714 REVIEW Ann Rheum Dis: first published as 10.1136/ard.55.10.700 on 1 October 1996. Downloaded from Current and potential future drug treatments for osteoporosis Sanjeev Patel Osteoporosis is the most common metabolic ture risk increases by a factor of 1.5 to 3.0.6 bone disease in the developed world and is Other determinants of osteoporotic fracture increasingly recognised as an important public are shown in table 1. health problem.' There is marked worldwide Drugs active on bone can be simplistically variation in its incidence. It is predicted that classified as those that inhibit bone resorption the incidence of hip fractures caused by or those that stimulate bone formation (table osteoporosis will increase, particularly in 2). The effects of these drugs on bone mineral developing countries.2 The human burden of density are summarised in fig 1. Drugs that osteoporosis is considerable, with increased stimulate bone formation lead to a direct morbidity and mortality, especially following increase in bone mineral density, whereas those osteoporotic hip fractures.' The current finan- that inhibit bone resorption result in limited cial burden is substantial, with estimated yearly increases in bone mineral density by costs of £750 million in the UK,' $10 billion in uncoupling bone turnover and allowing forma- the USA, and FF3.7 billion in France.3 The tion to continue in excess of resorption. This ability to measure bone mineral density and leads to an increase in bone mineral density thereby monitor response to intervention has due to filling in of the remodelling space (the been vital in the development ofpharmacologi- remodelling transient).7 It has been suggested cal treatments.
    [Show full text]
  • Free PDF Download
    European Review for Medical and Pharmacological Sciences 2018; 22: 4669-4676 Ipriflavone promotes osteogenesis of MSCs derived from osteoporotic rats A.-G. GAO1,2, Y.-C. ZHOU2, Z.-J. HU2, B.-B. LU2 1Department of Orthopedics, The First Affiliated Hospital Of Soochow University, Suzhou, China 2Department of Orthopedics, Wuxi People’s Hospital Affiliated to Nanjing Medical University, Wuxi, China Abstract. – OBJECTIVE: To explore whether celerated bone resorption, bone mass decrease, Ipriflavone could prevent postmenopausal oste- microstructure destruction and bone fragility oporosis (PMOP) and improve bone quality via elevation, thus eventually leading to high risk of promoting osteogenesis of bone marrow-de- fracture5. Therefore, PMOP is a serious problem rived mesenchymal stem cell (MSCs). 6 MATERIALS AND METHODS: MSCs were ex- that poses a great challenge in public health . In tracted from rats and identified using flow cy- recent years, hormone replacement therapy and tometry. Osteogenic specific genes and adipo- calcitonin intervention are the main treatments genic specific genes in MSCs were detected by for PMOP7. However, the long-term use of es- quantitative Real-time polymerase chain reac- trogen significantly increases the prevalence of tion (qRT-PCR). The effect of Ipriflavone on os- endometrial cancer and breast cancer8. Besides, teogenesis was detected by CCK-8 (cell count- the long-term use of calcitonin injection is incon- ing kit-8) assay, ALP activity detection, alizarin 3 red staining and Western blot, respectively. Fur- venient and expensive . Currently, Ipriflavone has thermore, ovariectomized PMOP rat model was been well recognized since it could effectively constructed. The effects of Ipriflavone on osteo- prevent PMOP9,10.
    [Show full text]
  • Targeting Cathepsin K for the Treatment of Osteoporosis – Focus
    Drugs or :he Future 2010, 35(8): 643-,;49 THOMSON Rf.CJTfRS \' (opvtlght ~ lOIO Prous Sd1.?no:•, SA U. <11 it~ lir.f:>nsor!=. At~ right~ r~~Q1~d CCC: 0.377-Lll82/W10 001: 10 1353/~of.2010 35 8 .152~'l'.2 F{E\/!EW J\f<TICLE TARGETING CATHEPSIN K FOR THE TREATMENT OF OSTEOPOROSIS: FOCUS ON ODANACATIB E.M. Lewiecki New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USA CONTENTS density (BMD) and bone strength are stable. II bone resorption SummJry .......... ....... .. , . .... ..... • ...... ... .643 exceeds bone formation, as occurs in postmenopausat estrogen· deficient women, there is a net loss of bone over time that may ulti· Introduction ........ ........ • .. .... .. • ..... ..... .. .643 mately result in osteoporosis and increased risk of fractures (1) . Cathepsin K inhibitors .......... .. ...... .. .... ... .... .645 Osteoporosis is a common disease associated with increased Conclusions ....... ....... .. .. .. ...... ....... .648 morbidity, increased mortality and high henlthcare costs due to frac­ Referencr.s .......... ..•. .. .... ... • . ... • .. .. , .. .648 tures (2). Bone resorption requires the attachment of an osteoclast to the bone surface by means of a "sealing zone" in order to create a self· SUMMARY contained compartment between the bone surface and the adjacent Cathepsin K is a lysosomal cysteine protease expressed by osteoclasts ruffled border of the osteoclast (3). The acidic microenvironment that degrades type I collagen during the process of bone remodeling. beneath the osteoclast demineralizes the bone and exposes the Postmenopovsal osteoporosis (PMO) is a disease of excessive bone underlylng matrix, which is then degraded through the action of cys­ tvrnover, wit/1 an imbalance between bone resorption and bone formo - teine proteases (4). Since cathepsin K is the most abundant cysteine tion that covses loss of bone strength and increased risk of fractures.
    [Show full text]
  • 10 Jahre UNIVERSUM INNERE MEDIZIN Liebe
    P.b.b. GZ02Z031655M, Benachrichtigungspostamt 1070 Wien unDie Fachzeitschrift versum der Österreichischen Gesellschaft für Innere Medizin InnereMedizinInnereMedizin Sonderausgabe aus Anlass des 10-jährigen Bestehens von UNIVERSUM INNERE MEDIZIN Österreichische Gesellschaft für Innere Medizin www.oegim.at 1010 Jahre Jahre InnereInnere MedizinMedizin FortschritteFortschritte undund KontroversenKontroversen ausaus derder Jubiläums-PerspektiveJubiläums-Perspektive MedMedia Falls unzustellbar,Falls bitte retour an:Verlag, MEDMEDIA 1.1, Seidengasse 9/Top Wien 1070 Verlags Ges.m.b.H. Fachkurzinformation siehe Seite 68 GRUSSWORT DES HERAUSGEBERS o. Univ.-Prof. Dr. Günter j. Krejs Herausgeber Universum Innere Medizin 10 Jahre UNIVERSUM INNERE MEDIZIN Relevanz und Aktualität zu bieten. Dafür danken wir ganz diese 10 Jahre, die hinter uns liegen, und helfen Sie mit, herzlich allen unseren vielen Autoren. dass UNIVERSUM INNERE MEDIZIN auch in der Zukunft Es ist ein besonderer Anlass und es erfüllt uns mit Freude, In dieser Jubiläumsausgabe haben Sie einen breiten Quer- erfolgreich sein wird. dass wir auf den Erfolg dieser letzten Jahre zurückblicken schnitt dessen, was wir in den verschiedensten Sparten dürfen. Eine große Zahl von Ärzten und Spezialisten aus den publiziert haben. Ich bin sicher, Sie werden diese Ihr verschiedensten Bereichen haben dazu beigetragen, Sie Jubiläumsausgabe mit Vergnügen lesen. Sie kommt auch immer sehr prompt über neueste Entwicklungen und neue- rechtzeitig zur 40. Jahrestagung der Österreichischen ste Diagnostik und Therapie zu informieren. Die kurze Zeit Gesellschaft für Innere Medizin, für die UNIVERSUM INNERE vom Erstellen der Manuskripte bis zum Druck (durch- MEDIZIN ein Eckpfeiler der Publikationen der Gesellschaft schnittlich 6 Wochen) erlaubt es, Information von größter wurde. Autoren und Leser, freuen Sie sich mit uns über o.
    [Show full text]